Amylyx Acquires Knopp Neurosciences, Expands ALS Pipeline
Ticker: AMLX · Form: 8-K · Filed: Jul 10, 2024 · CIK: 1658551
Sentiment: bullish
Topics: acquisition, pipeline-expansion, als
TL;DR
Amylyx just bought Knopp Neurosciences to boost its ALS drug pipeline, paying with stock.
AI Summary
Amylyx Pharmaceuticals, Inc. announced on July 9, 2024, the completion of its acquisition of 100% of the outstanding shares of privately held Knopp Neurosciences, Inc. This strategic move aims to expand Amylyx's pipeline with Knopp's investigational therapy for amyotrophic lateral sclerosis (ALS). The transaction involved the issuance of approximately 1.7 million shares of Amylyx common stock to Knopp shareholders.
Why It Matters
This acquisition strengthens Amylyx's position in the ALS market by adding a new investigational therapy, potentially leading to future revenue streams and improved patient outcomes.
Risk Assessment
Risk Level: medium — The acquisition introduces integration risks and the success of the acquired therapy is not guaranteed, impacting future financial performance.
Key Numbers
- 100% — Knopp Neurosciences ownership (Amylyx acquired full control of Knopp.)
- 1.7 million — Shares issued (Amylyx issued this many shares to Knopp shareholders.)
Key Players & Entities
- Amylyx Pharmaceuticals, Inc. (company) — Acquiring company
- Knopp Neurosciences, Inc. (company) — Acquired company
- July 9, 2024 (date) — Date of acquisition completion
- 1.7 million (dollar_amount) — Number of shares issued in the transaction
- amyotrophic lateral sclerosis (ALS) (disease) — Therapeutic area
FAQ
What was the primary purpose of Amylyx Pharmaceuticals acquiring Knopp Neurosciences?
The primary purpose was to expand Amylyx's pipeline with Knopp's investigational therapy for amyotrophic lateral sclerosis (ALS).
When did the acquisition of Knopp Neurosciences by Amylyx Pharmaceuticals officially complete?
The acquisition officially completed on July 9, 2024.
How did Amylyx Pharmaceuticals compensate the shareholders of Knopp Neurosciences?
Amylyx Pharmaceuticals compensated Knopp shareholders by issuing approximately 1.7 million shares of Amylyx common stock.
What is the therapeutic area of Knopp Neurosciences' investigational therapy?
Knopp Neurosciences' investigational therapy is for amyotrophic lateral sclerosis (ALS).
What percentage of Knopp Neurosciences did Amylyx Pharmaceuticals acquire?
Amylyx Pharmaceuticals acquired 100% of the outstanding shares of Knopp Neurosciences.
Filing Stats: 725 words · 3 min read · ~2 pages · Grade level 13.3 · Accepted 2024-07-10 07:09:00
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share AMLX Nasdaq Glo
- $35.1 m — and commercialization of Avexitide for $35.1 million, plus the aggregate amount of det
Filing Documents
- d853448d8k.htm (8-K) — 25KB
- 0001193125-24-177000.txt ( ) — 141KB
- amlx-20240709.xsd (EX-101.SCH) — 3KB
- amlx-20240709_lab.xml (EX-101.LAB) — 17KB
- amlx-20240709_pre.xml (EX-101.PRE) — 11KB
- d853448d8k_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. AMYLYX PHARMACEUTICALS, INC. Date: July 10, 2024 By: /s/ James M. Frates James M. Frates Chief Financial Officer